We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+8.76%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$13.8B
AUM Growth
-$581M
(-4%)
Cap. Flow
-$2.79B
Cap. Flow
% of AUM
-20.16%
Top 10 Holdings %
Top 10 Hldgs %
25.18%
Holding
905
New
29
Increased
148
Reduced
448
Closed
194
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$66.4M |
| 2 |
Valero Energy
VLO
|
+$28.9M |
| 3 |
SLB Ltd
SLB
|
+$24.8M |
| 4 |
BNY
Bank of New York Mellon
BNY
|
+$22.6M |
| 5 |
PepsiCo
PEP
|
+$20.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$182M |
| 2 |
Apple
AAPL
|
+$148M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$90.9M |
| 4 |
Amgen
AMGN
|
+$72.1M |
| 5 |
Tesla
TSLA
|
+$66.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.26% |
| 2 | Technology | 28.78% |
| 3 | Financials | 8.15% |
| 4 | Consumer Discretionary | 7.54% |
| 5 | Industrials | 7.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Microsoft
MSFT
$2.95T
| $822M | 5.94% |
2,414,019
-581,209
| -19% | -$182M |
|
|
2
Apple
AAPL
$4.81T
| $681M | 4.92% |
3,512,963
-847,077
| -19% | -$148M |
|
3
Merck
MRK
$312B
| $361M | 2.61% |
3,125,971
-344,091
| -10% | -$39.1M |
|
|
4
Alphabet (Google) Class A
GOOGL
$4.24T
| $356M | 2.57% |
2,972,136
-789,994
| -21% | -$90.9M |
|
5
Thermo Fisher Scientific
TMO
$195B
| $243M | 1.76% |
466,007
+13,304
| +3% | +$7.18M |
|
6
UnitedHealth
UNH
$396B
| $232M | 1.67% |
481,826
-54,658
| -10% | -$26.7M |
|
7
Regeneron Pharmaceuticals
REGN
$70.8B
| $220M | 1.59% |
305,618
-43,370
| -12% | -$33.4M |
|
8
NVIDIA
NVDA
$5.02T
| $211M | 1.53% |
4,998,450
-1,100,460
| -18% | -$36.5M |
|
9
Danaher
DHR
$127B
| $188M | 1.36% |
882,139
-176,703
| -17% | -$37.4M |
|
10
Procter & Gamble
PG
$345B
| $171M | 1.23% |
1,125,426
-98
| -0% | -$14.8K |
|
11
Visa
V
$677B
| $169M | 1.22% |
711,590
-84,357
| -11% | -$19.3M |
|
12
Eli Lilly
LLY
$1.05T
| $159M | 1.15% |
339,317
-145,090
| -30% | -$60.8M |
|
|
13
Amgen
AMGN
$198B
| $154M | 1.12% |
695,122
-310,684
| -31% | -$72.1M |
|
14
Amazon
AMZN
$2.66T
| $152M | 1.1% |
1,163,365
-14,743
| -1% | -$1.68M |
|
15
Vertex Pharmaceuticals
VRTX
$122B
| $140M | 1.01% |
396,562
+5,654
| +1% | +$1.91M |
|
16
Johnson & Johnson
JNJ
$603B
| $136M | 0.98% |
819,643
-43,858
| -5% | -$7.08M |
|
17
Gilead Sciences
GILD
$162B
| $130M | 0.94% |
1,681,795
+9,827
| +0.6% | +$784K |
|
18
Adobe
ADBE
$90.3B
| $129M | 0.94% |
264,568
-48,444
| -15% | -$19.5M |
|
19
Mastercard
MA
$476B
| $124M | 0.9% |
314,868
-57,321
| -15% | -$21.5M |
|
|
20
Alphabet (Google) Class C
GOOG
$4.22T
| $123M | 0.89% |
1,020,667
-373,636
| -27% | -$43.3M |
|
21
Palo Alto Networks
PANW
$279B
| $108M | 0.78% |
844,274
+29,002
| +4% | +$3.02M |
|
22
ServiceNow
NOW
$105B
| $104M | 0.75% |
922,260
+202,835
| +28% | +$20.3M |
|
|
HOLX
23
DELISTED
Hologic
HOLX
| $103M | 0.74% |
1,267,695
+10,054
| +0.8% | +$822K |
|
|
SGEN
24
DELISTED
Seagen Inc. Common Stock
SGEN
| $102M | 0.74% |
529,779
-47,841
| -8% | -$9.5M |
|
25
Broadcom
AVGO
$1.84T
| $99.7M | 0.72% |
1,148,920
+92,810
| +9% | +$6.62M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2023 Portfolio in Review
As of Q2 2023, Candriam SCA held 905 positions worth $13.8B, down 4% from $14.4B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Candriam SCA withdrew a net $2.79B in Q2 2023, closing 194 positions and reducing 448 holdings. Its most notable exit was Thomson Reuters, an estimated $19.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 31% of assets, up from 31% a quarter earlier, followed by Technology and Financials.
Against the trend, Candriam SCA opened a new position in Vir Biotechnology worth $8.7M.
- Candriam SCA's largest Q2 2023 buy was Vir Biotechnology: 354,645 shares worth $8.7M.
- Candriam SCA added most to Lam Research in Q2 2023, an estimated $66.4M increase.
- Candriam SCA's biggest Q2 2023 reduction was Microsoft, cutting an estimated $182M.
- Candriam SCA fully exited Thomson Reuters in Q2 2023, selling an estimated $19.8M.
- Candriam SCA's ten largest holdings make up 25% of its $13.8B portfolio in Q2 2023.
- Candriam SCA opened 29 new positions and closed 194 in Q2 2023.
- Candriam SCA's portfolio value fell 4% quarter-over-quarter to $13.8B.
Based on Candriam SCA's 13F filing for Q2 2023, filed 8 Aug 2023.